US2021269455A1PendingUtilityA1

Quinazoline analogs as receptor tyrosine kinase inhibitors

77
Assignee: ARRAY BIOPHARMA INCPriority: Aug 14, 2003Filed: Oct 13, 2020Published: Sep 2, 2021
Est. expiryAug 14, 2023(expired)· nominal 20-yr term from priority
Inventors:Eli M. WallaceGeorge T. TopalovJoseph P. LyssikatosAlexandre Joseph BuckmelterQian Zhao
C04B 35/632A61P 29/00A61P 35/00A61P 35/04C07D 413/14C07D 498/04C07D 413/12C07D 417/14C07D 239/94C07D 498/10C07D 401/12
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . A method of inhibiting the activity of ErbB2 comprising administering an effective amount of a compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
         4 . The method of  claim 3 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.